	US 11,938,219 B2
	Synthetic extracellular vesicles for novel therapies
Yong Zhang, Los Angeles, CA (US); Xiaojing Shi, Los Angeles, CA (US); and Qinqin Cheng, Los Angeles, CA (US)
Assigned to University of Southern California, Los Angeles, CA (US)
Appl. No. 16/634,857
Filed by University of Southern California, Los Angeles, CA (US)
PCT Filed Jul. 27, 2018, PCT No. PCT/US2018/044251 § 371(c)(1), (2) Date Jan. 28, 2020, PCT Pub. No. WO2019/027847, PCT Pub. Date Feb. 7, 2019.
Claims priority of provisional application 62/538,669, filed on Jul. 29, 2017.
Prior Publication US 2020/0405640 A1, Dec. 31, 2020
Int. Cl. A61K 9/12 (2006.01); A61K 9/127 (2006.01); A61K 31/4745 (2006.01); C07K 14/71 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)

CPC A61K 9/1271 (2013.01) [A61K 9/1277 (2013.01); A61K 31/4745 (2013.01); C07K 14/71 (2013.01); C07K 16/2809 (2013.01); C07K 16/283 (2013.01); C07K 16/32 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/41 (2013.01); C07K 2319/42 (2013.01)]

15 Claims

1. An isolated engineered extracellular vesicle comprising a first antigen binding domain that comprises an anti-EGFR scFv antibody fragment and a second antigen binding domain that comprises an anti-CD3 scFv antibody fragment and, the first and second antigen binding domains being fused to one or more extracellular vesicle addressing domains expressed on the surface of the vesicle, wherein the one or more extracellular vesicle addressing domain comprises platelet-derived growth factor receptor (PDGFR) transmembrane domain.